

June 1997

Volume 4, Number 2

In This Issue...

Changes to Formulary		1
Revised Drug Administration Policies	2	
Olanzapine		2
Treatment of <i>Helicobacter pylori</i>		4
Phenytoin & Folic acid drug interaction	5	

Changes to Formulary

Additions

1. Clarithromycin 250mg, 500mg tablets (Biaxin®)
 - macrolide antibiotic
 - restricted for management of *Helicobacter pylori* associated peptic ulcer disease and for prophylaxis of *Mycobacterium Avium Complex* (MAC) infections
 - cost: refer to treatment guidelines for *H. pylori* infections, page 4
2. Olanzapine 5mg, 7.5mg, 10mg tablets (Zyprexa®)
 - atypical antipsychotic agent pharmacologically and structurally similar to clozapine
 - cost: refer to page 2 for review
3. Tacrolimus (FK506) 1mg, 5mg capsules, 5mg/mL ampoule (Prograf®)
 - immunosuppressive agent indicated for prophylaxis of organ rejection in patients receiving solid organ transplants.
 - may also be used in bone marrow transplant recipients who develop cyclosporine-resistant/intolerant graft-versus-host disease
 - replaces cyclosporine in regimens

4. Baclofen intrathecal 0.05mg/mL, 2mg/mL ampoule (Lioresal®)
 - intrathecal infusion for treatment of spasticity that is intractable to oral baclofen and other antispasticity drugs

Deletions

1. Methocarbamol injection 100mg/mL (Robaxin®)
 - no usage in past 3 years
2. Pentagastrin injection 0.25mcg/mL (Peptavlon®)
 - no usage in past 3 years
3. Pepsin solution 3.3mg/mL (Fermentol®)
 - no usage in past 3 years
4. Triamcinolone diacetate 25mg/mL, 40mg/mL (Aristocort® intralesional)
 - alternative: triamcinolone acetonide 10mg/mL, 40mg/mL (Kenalog®)
5. Pentazocine 50mg tabs, 50mg/mL injection (Talwin®) (effective Sept 1, 1997)
 - minimal usage in past 3 years
 - alternatives: morphine, anileridine
6. Flucloxacillin 250mg capsules (Fluclox®)
 - discontinued by manufacturer

EDITORIAL STAFF:

Karen Shalansky, Pharm.D.
Peter Loewen, Pharm.D.
Rubina Sunderji, Pharm.D.

The Drug and Therapeutics Newsletter is a publication of the Clinical Service Unit - Pharmaceutical Sciences at Vancouver Hospital and Health Sciences Centre. For contact information, call (604) 875-4077 or find us on the Web at www.research.vhsc.ubc.ca/pharmacy/

Updated Policies & Procedures

Revised Drug Administration Policies

The following changes will be added to the next Parenteral Drug Therapy Manual (PDTM) update:

- Table 1 illustrates the recommended dosages of Vitamin K for the treatment of warfarin-induced hypoprothrombinemia:

INR	Recommendation
< 6 and no bleeding	No vitamin K. Hold warfarin until INR in therapeutic range.
6-9 and no bleeding	Hold warfarin until INR in therapeutic range. May give vitamin K 1-2mg SC or slow IV. May repeat in 24 hours.
> 9 and no bleeding	Vitamin K 3-5mg SC or slow IV. May repeat in 6 hours.
Serious bleed	Vitamin K 10mg SC or slow IV. May repeat in 6 hours. Supplement with fresh frozen plasma as required.

- The Operating Room (OR) has been added as a critical care area
- Octreotide may be given by subcutaneous (SC) infusion for palliation of intractable vomiting
- Methotrimeprazine may be administered by SC injection on any nursing unit
- Diltiazem parenteral may be administered in any critical care area and may also be prescribed for the prevention of arterial spasm
- Amrinone may be prescribed for augmentation of myocardial contraction for assessment of myocardial contractile reserve with imaging

New Drugs/Drug Products

Olanzapine: Atypical Antipsychotic

Karen Shalansky, Pharm.D.
Reviewed by Dr. R. Lam, Psychiatry
and A. Runikis, B.Sc. (Pharm)

Olanzapine is a new atypical antipsychotic drug indicated for acute and maintenance treatment of schizophrenia and related psychotic disorders in which positive (hallucinations, delusions, hostility) and/or negative (blunted affect, emotional and social withdrawal)¹ symptoms are prominent. Olanzapine represents an alternative to conventional neuroleptic therapy (e.g. haloperidol), with the advantage of causing fewer extrapyramidal symptoms (EPS).

Comparable Formulary Agents

Clozapine and risperidone are two atypical antipsychotics available on formulary at VHHSC. Olanzapine is structurally and pharmacologically related to clozapine. It has affinity for various neurotransmitter binding sites including serotonin type 2 (5-HT₂) and dopamine receptors. Although there have been no head-to-head trials, clinical effects of olanzapine appear similar to those of clozapine in schizophrenic patients in improving both positive and negative symptoms. As opposed to clozapine, olanzapine has never been studied in patients with refractory schizophrenia.

Compared to haloperidol, olanzapine produces similar decreases in positive symptoms of schizophrenia, but is superior in reducing negative symptoms.^{2,3} As well, it is associated with a lower incidence of EPS, especially dystonic reactions, and elevation of serum prolactin levels.

Pharmacokinetics

Olanzapine is 93% bound to plasma proteins and is eliminated extensively by

first pass metabolism in the liver.⁴ The half-

Treatment of *Helicobacter pylori* in association with Peptic Ulcer Disease

Dr. K. Shalansky, C. Hughes, Dr. P. Loewen, Pharmacy
Reviewed by Dr. D. Carr, Dr. E. Yoshida, Gastroenterology

It is now accepted that the majority of peptic ulcers occur secondary to either *H. pylori* infection or non-steroidal anti-inflammatory drugs (NSAIDs).¹ *H. pylori* is a gram negative bacillus which colonizes the human gastric mucosa.² The percentage of peptic ulcers associated with *H. pylori* infection is as follows³:

Gastric ulcers (GU): ~ 70%
Duodenal ulcers (DU): > 95%

Indications for anti-*H. Pylori* Therapy

All patients with a documented DU or GU associated with *H. pylori* infection should receive antimicrobial therapy. The presence of *H. pylori* can be determined by endoscopy with biopsy or non-invasively through serologic antibody testing or breath tests for urea.^{1,3} For practical purposes, in patients with an uncomplicated DU, empiric antibiotic therapy without *H. pylori* testing has been advocated due to the high association with this organism.^{3,4}

Treatment Strategies for *H. pylori*

According to the consensus guidelines, two regimens are currently recommended for eradication of *H. pylori* (Table 3).^{3,5} Both regimens are effective with one week of therapy. The addition of omeprazole in the quadruple regimen enhances symptom relief and improves eradication by ~ 5%.

Quadruple therapy is considered the "gold standard" regimen, however, patient compliance may be hindered by its complexity. Triple therapy offers a simpler BID regimen, albeit slightly less efficacious and more expensive. Dual therapy with omeprazole plus amoxicillin 1g BID or clarithromycin 500mg TID x 2 weeks are not recommended due to lower success rates of 50-80%.

Adverse effects (primarily metallic taste, nausea and diarrhea) result in ~ 5% patient withdrawal. Clarithromycin inhibits the Cyp 3A enzyme system which can result in toxic levels of cyclosporine, theophylline, cisapride, and non-sedating antihistamines (terfenadine, astemizole).

Table 3: Eradication of *H. pylori* infection: regimens and costs

Recommended Regimens (x 7 days)	Success Rate	Cost/7 days ¹
QUADRUPLE THERAPY Bismuth Subsalicylate 30mL (or ii tablets) QID Metronidazole 250mg QID Tetracycline 500mg QID Omeprazole 20mg BID	94-98%	\$44.61 \$12.13 \$0.56 \$1.12 \$30.80
TRIPLE THERAPY Metronidazole 500mg BID (or Amoxicillin 1g BID) Clarithromycin 500mg BID Omeprazole 20mg BID	86-91%	\$72.76 or \$74.70 \$0.56 (\$2.40) \$41.40 \$30.80

¹ based on VHHSC acquisition cost

Follow-up

Once cure has been achieved, reinfection rates are less than 0.5%.³ Eradication of *H. pylori* should be confirmed 4 weeks after completion of antibiotic treatment for complicated, large or refractory ulcers. Antisecretory therapy should be continued until *H. pylori* cure has been confirmed in these cases. Once ulcer healing is complete and *H. pylori* eradicated, maintenance antisecretory therapy (e.g. ranitidine 150mg HS) is only warranted in high risk patients where recurrence of bleeding may cause death.³

References

Pre-printed *H.pylori* eradication orders are now available from printing for all wards.

1. Anon. Drugs for treatment of peptic ulcers. *Med Lett Drugs Ther* 1994;36(issue 927):65-7.
2. Burette A, Glupczynski Y. *Infection* 1995;23:S44-S52.
3. Soll AH. Medical treatment of peptic ulcer disease. *JAMA* 1996;275:622-9.
4. Rauws EAJ, van der Hulst RWM. Current guidelines for the eradication of *Helicobacter pylori* in peptic ulcer disease. *Drugs* 1995;50:984-90.
5. Walsh JH, Peterson WL. The treatment of *Helicobacter pylori* infection in the management of peptic ulcer disease. *NEJM* 1996;333:984-91.

(Continued from page 2)

life is approximately 27 hours (range 21 to 54 hours) with steady-state concentrations reached in about 1 week.⁴

Adverse Effects

The more common adverse effects include postural hypotension, dizziness, somnolence, dry mouth and akathisia. Less common side effects are constipation, weight gain (average 2.8 kg), transient elevations of hepatic transaminases, syncope (0.6%), and seizures (0.9%).^{4,5}

The potential advantage of olanzapine over clozapine is that it does not appear to cause severe neutropenia or agranulocytosis and so does not require as close monitoring of blood counts. Although there are no reports in the literature, there has been one case of olanzapine-related agranulocytosis which occurred at VH-UBC site and 2 cases of exacerbation of agranulocytosis by olanzapine reported to the BC Drug and Poison Information Centre (DPIC) from Riverview Hospital.

Dose and Cost

Olanzapine is initiated at 5-10mg/day, with gradual 5mg weekly adjustments to a maximum daily dose of 20mg. The target range is usually 10-15mg daily. Orthostasis, dizziness and weight gain may be minimized with a lower starting dose of 5mg/day and more gradual upward titration. Refer to Table 2 for cost comparison of atypical antipsychotic agents.

Place in Therapy

Table 2. Cost comparison of atypical antipsychotics

Drug	Comparable Upper Range Dose and Cost ¹
Risperidone	8mg/day = \$7.64/day
Clozapine	450mg/day = \$17.00/day
Olanzapine	15mg/day = \$10.14/day

¹ based on VHHSC acquisition cost

Olanzapine has been approved by Pharmacare for patients who have failed one typical antipsychotic agent (e.g. haloperidol) or who develop intolerable adverse effects to these agents. In contrast, clozapine is indicated in patients who are refractory to typical antipsychotics (at least 2 chemically unrelated drugs) or who have intolerable EPS. More direct and long-term safety comparisons with clozapine are required to determine the exact role of olanzapine in therapy.

Conclusions

Olanzapine, an atypical antipsychotic agent, is pharmacologically and structurally similar to the formulary drug clozapine. Although there are no head-to-head comparisons, the clinical effects of both agents appear to be similar in schizophrenic patients. Both agents improve positive and negative symptoms and are associated with a lower incidence of EPS compared to haloperidol. The potential advantage of olanzapine over clozapine appears to be its side effect profile. Initial reports suggest that olanzapine use is not associated with the development of severe neutropenia or agranulocytosis as has been described with clozapine. Unfortunately, local reports suggest that this complication may not be unique to clozapine.

References

1. Ontario College of Pharmacists. Risperidone.
2. New Drugs-Drug News. 1993;11(4):1.
3. Beasley Jr CM et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. *Neuropsychopharmacol* 1996;14:111-23.
4. Micromedex Drug Consults 1996.
5. Tabarsi E. Olanzapine. For your Inpharmation Pharmacy Newsletter, Riverview Hospital. 1996;16(9):1-2.

Drug Interaction: Phenytoin and Folic Acid

James Conklin, Pharmacy Resident

Reviewed by Dr. P. Loewen, Dr. K. Shalansky, Pharmacy and Dr. M. Jones, Neurology

The interaction between phenytoin and folic acid is commonly cited in major drug interaction texts.^{1,2,3} However, the interaction is more complex than it may initially appear. The most commonly cited effect is that of decreased serum phenytoin concentrations when folic acid is taken concurrently.^{1,2} It has also been shown that phenytoin can decrease folate concentrations in patients.⁴ This drug-nutrient interaction is dual and interdependent.⁵ While some clinicians advocate avoiding this drug combination, others theorize a benefit of supplementing all phenytoin treated patients with folic acid. Is there a common ground?

Effects of Folate on Phenytoin

There are few controlled studies of the effect of folic acid supplementation on phenytoin pharmacokinetics. Those that have been published come to conflicting conclusions.⁶ Some trials have demonstrated decreases in serum phenytoin concentrations to varying degrees after 1-2 weeks of combined therapy.^{6,7} Doses of folic acid ranged from 5-30mg/day. Other trials have not shown a decrease in serum phenytoin levels after 1mg or 5mg per day of folic acid.⁸

Decreased phenytoin concentrations may be due

Folic acid may decrease phenytoin concentrations to varying degrees. Scattered reports of loss of seizure control are not supported by controlled trials.

to an increase in the metabolism of phenytoin by folic acid. An increase in the parahydroxylated metabolite of phenytoin in the urine, corresponding to a decrease in serum phenytoin concentration, has been observed with the initiation of folic acid.^{9,10} Analysis of the kinetics of this interaction suggests that folic acid supplementation causes an increase in the affinity of the enzyme complex for phenytoin resulting a decrease in the Michaelis-Menten rate constant (K_m) with no effect on the maximum rate of metabolism (V_{max}).¹¹

Conversely, a retrospective analysis of this interaction concluded that there was no change in K_m , but an increase in V_{max} .¹² Both findings support the suggestion that the interaction is highly patient specific.

Clinically, while some authors report a loss of seizure control when folic acid is added to phenytoin therapy^{7,13-15}, a review of eight large controlled studies, mostly double blind, showed no significant difference in mean seizure frequency with combination therapy⁶.

Effects of Phenytoin on Folate

The prevalence of subnormal serum folate concentrations in patients receiving chronic phenytoin therapy ranges from 27-91%.⁴ Progression to megaloblastic anemia occurs in <1% of patients.¹⁶ The development of subnormal folate concentrations in epileptic patients on anticonvulsant therapy is not consistently related to phenytoin dose, duration of therapy or serum concentrations⁶, although such relationships have been suggested^{8,17-19}. The mechanism by which phenytoin causes a decrease in folate concentrations is not understood. Possible hypotheses include: 1)

Phenytoin can cause decreased serum folate concentrations, although megaloblastic anemia is rare.

malabsorption of dietary folate due to pH changes caused by phenytoin²⁰, 2) malabsorption of dietary folate due to inhibition of intestinal enzymes by phenytoin²¹, 3) phenytoin-induced impairment of folate transport into tissue²², and 4) phenytoin-induction of liver enzymes which are dependent on folate as a cofactor²³.

Controversy surrounds the question of neurological and psychiatric implications of a folate deficiency resulting from long-term phenytoin

(Continued from page 5)

therapy. No controlled study has found any significant change in mentation associated with phenytoin therapy in folate-deficient epileptic patient populations.²⁴⁻²⁷

Conclusions

The phenytoin-folic acid interaction has yet to be fully elucidated. While folic acid may decrease serum phenytoin concentrations to varying degrees, folic acid levels may also decrease during phenytoin therapy. From the literature, it appears that the majority of patients are not affected significantly by these interactions. Controlled trials have not shown a significant increase in seizure activity when folic acid is added to phenytoin therapy, and megaloblastic anemia occurs rarely.

In conclusion, phenytoin therapy should not preclude the use of folic acid in patients in whom folic acid is deemed necessary. Of note, it is currently recommended that all women of childbearing age consume folic acid 0.4mg/day to prevent neural tube defects in offspring.²⁸ It would therefore be prudent to provide folic acid to all women of childbearing age who are receiving phenytoin. If folic acid supplementation is initiated in a patient stabilized on a regimen of phenytoin, serum phenytoin levels should be re-evaluated in 1-4 weeks to assess the impact of this interaction.

References

1. Drug Interaction Facts. St. Louis: Facts and Comparisons; 1994:383.
2. Hansten P, Horn JR. Drug Interactions and Updates. Applied Therapeutics; 1993:350.
3. Micromedex. "Phenytoin." Drug evaluation monographs. Vol. 91 exp. 2/28/97.
4. Reynolds EH. Diphenylhydantoin: hematologic aspects of toxicity. In: Woodbury DM, Penry JK, Schmidt RP, eds. Antiepileptic drugs. New York: Raven Press; 1972: 247-62.
5. Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ. Phenytoin-folic acid interaction. Ann Pharmacother 1995;29:726-35.
6. Rivey MP, Schottelius DD, Berg MJ. Phenytoin-folic acid: a review. Drug Intell Clin Pharm 1984;18:292-301.
7. Bayliss EM, Crowley JM, Preece JM, Sylvester PE, Marks V. Influence of folic acid on blood-phenytoin levels. Lancet 1971;1:62-4.
8. Berg MJ, Fincham RW, Ebert BE, Schottelius DD. Phenytoin pharmacokinetics: before and after folic acid administration. Epilepsia 1992;33(4):712-20.
9. Makki KA, Perucca E, Richens A. Metabolic effects of folic acid replacement therapy in folate-deficient epileptic patients. In: Johannessen SI, Morselli PI, Pippenger CE, et al., eds. Antiepileptic therapy: advances in drug monitoring. New York: Raven Press; 1980:391-6.
10. Kutt H, Winters W, McDowell FH. Depression of parahydroxylation of diphenylhydantoin by antituberculosis chemotherapy. Neurology 1966;16:594-602.
11. Berg MJ, Rivey MP, Vern BA. Phenytoin-folic acid interaction—a preliminary report. Ther Drug Monitor 1983;5:395-9.
12. MacCosbe PE, Toomey K. Interaction of phenytoin and folic acid. Clin Pharm 1983;2:362-9.
13. Strauss RG, Bernstein R. Folic acid and dilantin antagonism in pregnancy. Obstet Gynecol 1974;44:345-8.
14. Arellano-Isaac C, Rivera-Calimlim L. Phenytoin neurotoxicity. Drug Ther 1978;8:152-63.
15. Chanarin I. Effects of anticonvulsant drugs. In: Botez MI, Reynolds EH, eds. Folic acid in neurology, psychiatry, and internal medicine. New York: Raven Press, 1979:75-85.
16. Flexner JM, Hartman RC. Megaloblastic anemia associated with anticonvulsant drugs. Am J Med 1960;28:386-96.
17. Houben PF, Hommes OR, Knaven PJ. Anticonvulsant drugs and folic acid in young mentally retarded epileptic patients. A study of serum folate, fit frequency and I.Q. Epilepsia 1971;21:235-47.
18. Klipstein FA. Subnormal serum folate and macrocytosis associated with anticonvulsant drug therapy. Blood 1964;23:68-85.
19. Reynolds EH, Mattson RH, Gallagher BB. Relationships between serum and cerebrospinal fluid anticonvulsant drug and folic acid concentrations in epileptic patients. Neurology 1972;22:841-4.
20. Benn A, Swan CH, Cooke WT, et al. Effect of intraluminal pH on the absorption of pteromonoglutamic acid. Br Med J 1971;1:148-50.
21. Rosenberg IH, Streiff RR, Godwin HA, Castle WB. Impairment of intestinal deconjugation of dietary folate—a possible explanation of megaloblastic anemia associated with phenytoin therapy. Lancet 1968;2:530-2.
22. Krumdieck CL, Fukushima K, Fukushima T, Shiota T, Butterworth CE, Jr. A long-term study of the excretion of folate and pterins in a human subject after ingestion of ¹⁴C folic acid, with observations on the effect of diphenylhydantoin administration. Am J Clin Nutr 1978;31:88-93.
23. Maxwell JD, Hunter J, Stewart DA, Ardeman S, Williams R. Folate deficiency after anticonvulsant drugs: an effect of hepatic enzyme induction. Br Med J 1972;1:297-9.
24. Grant RH, Shores OP. Folic acid in folate-deficient patients with epilepsy. Br Med J 1970;4:644-8.
25. Mattson RH, Gallagher BB, Reynolds EH, Glass D. Folate therapy in epilepsy. Arch Neurol 1973;29:78-81.
26. Jensen ON, Olesen OV. Subnormal serum folate due to anticonvulsant therapy. A double-blind study of the effect of folic acid treatment in patients with drug-induced subnormal serum folate. Arch Neurol 1970;22:181-2.
27. Bowe JC, Cornish EJ, Dawson M. Evaluation of folic acid supplements in children taking phenytoin. Dev Med Child Neurol 1971;13:343-54.
28. United States Public Health Service 1992.